Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis

Abstract

SummaryImmune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. However, their use is frequently associated with immune‐related adverse events (irAEs) potentially affecting any organ. The mechanisms mediating such irAEs remain poorly understood and biomarkers to predict the development of irAEs are lacking. Growing evidence shows the importance of self‐antigens in mediating irAEs during ICI therapy, in particular the well‐described melanocyte differentiation antigens in melanoma patients. This review will focus on two novel classes of self‐antigens involved in mediating autoimmune skin toxicity and pneumonitis in non‐small cell lung cancer patients treated with immunotherapy. T cells specific for these self‐antigens are thought to not only mediate irAEs but are thought to simultaneously mediate anti‐tumor responses and are therefore associated with both autoimmune toxicity and response to ICI therapy. We further discuss emerging cellular and proteomic immune signatures of irAEs that may serve as biomarkers to help predict which patients are at higher risk of developing these irAEs. The determination of new tumor antigens involved in ICI therapy and the identification of related biomarkers brings us a step forward in the mechanistic understanding of ICIs and will help to monitor patients at higher risk of developing irAEs. Lastly, we discuss the current challenges in collecting research samples for the study of ICI‐related mechanisms and in distinguishing between immune signatures of response and those of irAEs.